Literature DB >> 34602651

CXCR5+CD8+ T cells: A Review of their Antibody Regulatory Functions and Clinical Correlations.

Steven M Elzein1, Jason M Zimmerer2, Jing L Han2,3, Bryce A Ringwald1, Ginny L Bumgardner4.   

Abstract

CD8+ T cells have conventionally been studied in relationship to pathogen or tumor clearance. Recent reports have identified novel functions of CXCR5+CD8+ T cells that can home to lymphoid follicles, a key site of antibody production. In this review we provide an in-depth analysis of conflicting reports regarding the impact of CXCR5+CD8+ T cells on antibody production and examine the data supporting a role for antibody-enhancement (B cell "helper") and antibody-downregulation (antibody-suppressor) by CXCR5+CD8+ T cell subsets. CXCR5+CD8+ T cell molecular phenotypes are associated with CD8-mediated effector functions including distinct subsets that regulate antibody responses. Co-inhibitory molecule PD-1, among others, distinguish CXCR5+CD8+ T cell subsets. We also provide the first in-depth review of human CXCR5+CD8+ T cells in the context of clinical outcomes and discuss the potential utility of monitoring the quantity of peripheral blood or tissue infiltrating CXCR5+CD8+ T cells as a prognostic tool in multiple disease states.

Entities:  

Keywords:  Antibody; CXCR5+CD8+T cells

Mesh：

Substances：

Year:  2021        PMID： 34602651      PMCID： PMC8486376          DOI： 10.4049/jimmunol.2100082

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.426


  77 in total

1.  PD-1+ stemlike CD8 T cells are resident in lymphoid tissues during persistent LCMV infection.

Authors:  Se Jin Im; Bogumila T Konieczny; William H Hudson; David Masopust; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-07       Impact factor: 11.205

2.  Follicular cytotoxic CD8 T cells present high cytokine expression, and are more susceptible to Breg-mediated suppression in non-small cell lung cancer.

Authors:  Qin-Yun Ma; Jun Chen; Jun Zhao
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

3.  Antibody-suppressor CD8+ T Cells Require CXCR5.

Authors:  Jason M Zimmerer; Bryce A Ringwald; Steven M Elzein; Christina L Avila; Robert T Warren; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  Transplantation       Date:  2019-09       Impact factor: 4.939

Review 4.  A Portrait of CXCR5+ Follicular Cytotoxic CD8+ T cells.

Authors:  Di Yu; Lilin Ye
Journal:  Trends Immunol       Date:  2018-10-28       Impact factor: 16.687

5.  Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy.

Authors:  Guillaume Churlaud; Fabien Pitoiset; Fadi Jebbawi; Roberta Lorenzon; Bertrand Bellier; Michelle Rosenzwajg; David Klatzmann
Journal:  Front Immunol       Date:  2015-04-15       Impact factor: 7.561

6.  The transcription factor Runx3 guards cytotoxic CD8+ effector T cells against deviation towards follicular helper T cell lineage.

Authors:  Qiang Shan; Zhouhao Zeng; Shaojun Xing; Fengyin Li; Stacey M Hartwig; Jodi A Gullicksrud; Samarchith P Kurup; Natalija Van Braeckel-Budimir; Yao Su; Matthew D Martin; Steven M Varga; Ichiro Taniuchi; John T Harty; Weiqun Peng; Vladimir P Badovinac; Hai-Hui Xue
Journal:  Nat Immunol       Date:  2017-06-12       Impact factor: 25.606

7.  HIV-Specific CD8+ T Cells Exhibit Reduced and Differentially Regulated Cytolytic Activity in Lymphoid Tissue.

Authors:  Morgan A Reuter; Perla M Del Rio Estrada; Marcus Buggert; Constantinos Petrovas; Sara Ferrando-Martinez; Son Nguyen; Alberto Sada Japp; Yuria Ablanedo-Terrazas; Amaranta Rivero-Arrieta; Leticia Kuri-Cervantes; Heidi M Gunzelman; Emma Gostick; David A Price; Richard A Koup; Ali Naji; David H Canaday; Gustavo Reyes-Terán; Michael R Betts
Journal:  Cell Rep       Date:  2017-12-19       Impact factor: 9.423

8.  High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors.

Authors:  Jolanda Brummelman; Emilia M C Mazza; Giorgia Alvisi; Federico S Colombo; Andrea Grilli; Joanna Mikulak; Domenico Mavilio; Marco Alloisio; Francesco Ferrari; Egesta Lopci; Pierluigi Novellis; Giulia Veronesi; Enrico Lugli
Journal:  J Exp Med       Date:  2018-08-28       Impact factor: 14.307

Review 9.  CXCR5+ CD8 T Cells: Protective or Pathogenic?

Authors:  Kristen M Valentine; Katrina K Hoyer
Journal:  Front Immunol       Date:  2019-06-18       Impact factor: 7.561

10.  CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.

Authors:  Bithi Chatterjee; Yun Deng; Angelika Holler; Nicolas Nunez; Tarik Azzi; Liliana Danusia Vanoaica; Anne Müller; Hana Zdimerova; Olga Antsiferova; Andrea Zbinden; Riccarda Capaul; Johannes H Dreyer; David Nadal; Burkhard Becher; Mark D Robinson; Hans Stauss; Christian Münz
Journal:  PLoS Pathog       Date:  2019-05-30       Impact factor: 6.823
View more
  2 in total

1.  Antibody-suppressor CXCR5+ CD8+ T cellular therapy ameliorates antibody-mediated rejection following kidney transplant in CCR5 KO mice.

Authors:  Jason M Zimmerer; Jing L Han; Chelsea M Peterson; Qiang Zeng; Bryce A Ringwald; Clarissa Cassol; Sachi Chaudhari; Madison Hart; Jessica Hemminger; Anjali Satoskar; Mahmoud Abdel-Rasoul; Jiao-Jing Wang; Robert T Warren; Zheng J Zhang; Christopher K Breuer; Ginny L Bumgardner
Journal:  Am J Transplant       Date:  2022-02-15       Impact factor: 9.369

2.  Heterogenous CD8+ T Cell Maturation and 'Polarization' in Acute and Convalescent COVID-19 Patients.

Authors:  Igor V Kudryavtsev; Natalia A Arsentieva; Zoia R Korobova; Dmitry V Isakov; Artem A Rubinstein; Oleg K Batsunov; Irina V Khamitova; Raisa N Kuznetsova; Tikhon V Savin; Tatiana V Akisheva; Oksana V Stanevich; Aleksandra A Lebedeva; Evgeny A Vorobyov; Snejana V Vorobyova; Alexander N Kulikov; Maria A Sharapova; Dmitrii E Pevtsov; Areg A Totolian
Journal:  Viruses       Date:  2022-08-28       Impact factor: 5.818
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.